ERA-EDTA Symposium 2018

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ESC Congress 2018

On August 25th, 2018, Resverlogix supported a satellite symposium at the European Society of Cardiology (ESC) Congress in Munich, Germany: "LDL-c: Done Deal, Next Epigenetics?"

Symposium Agenda

Introduction - Ulrich Laufs, MD – Leipzig, Germany.

Erik Stroes, MD – Amsterdam, Netherlands. "The real residual risk in patients with CVD & diabetes: The promise of epigenetics."

Jorge Plutzky, MD – Boston, USA. "Understanding epigenetics: The potential rationale for BET inhibition in management of CVD."

Kausik Ray, MD - London, UK. "A clinical view on BET inhibition in targeting residual risk in CVD and diabetes."

Discussion & Summary. Co-Chairmen: Kausik Ray, MD and Ulrich Laufs, MD.

Video Presentations & Symposium Highlights can be accessed HERE